With 1.84 million shares changed hands, the volume of the stock remained lighter than its average volume of 2.82 million shares. During the session, the Medical Devices company that operates in wider Healthcare sector, reached to the highest price of $1.53 whereas the lowest price it dropped to was $1.17. The 52-week range on NUWE shows that it touched its highest point at $27.61 and its lowest point at $0.92 during that stretch. It currently has a 1-year price target of $16.00. Beta for the stock currently stands at 0.32.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of NUWE was down-trending over the past week, with a drop of -7.52%, but this was up by 9.82% over a month. Three-month performance dropped to -32.42% while six-month performance fell -56.54%. The stock lost -92.83% in the past year, while it has gained 10.81% so far this year. A look at the trailing 12-month EPS for NUWE yields -116.60 with Next year EPS estimates of -1.81. For the next quarter, that number is -0.43. This implies an EPS growth rate of 90.42% for this year and 95.32% for next year.
Float and Shares Shorts:
At present, 1.87 million NUWE shares are outstanding with a float of 1.12 million shares on hand for trading. On 2024-10-31, short shares totaled 0.32 million, which was 1727.0 higher than short shares on 1727654400. In addition to Mr. Nestor Jaramillo Jr. as the firm’s President, CEO & Director, Mr. Robert B. Scott serves as its Chief Financial Officer.
Institutional Ownership:
Through their ownership of 0.0146 of NUWE’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-06-30, NUWE reported revenue of $2367000.0 and operating income of $-1532000.0. The EBITDA in the recently reported quarter was $-1448000.0 and diluted EPS was $1.74.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential. With NUWE analysts setting a high price target of 16.0 and a low target of 16.0, the average target price over the next 12 months is 16.0. Based on these targets, NUWE could surge 1200.81% to reach the target high and rise by 1200.81% to reach the target low. Reaching the average price target will result in a growth of 1200.81% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of $-36.57 being high and $-40.71 being low. For NUWE, this leads to a yearly average estimate of $-38.64. Based on analyst estimates, the high estimate for the next quarter is $0 and the low estimate is $0. The average estimate for the next quarter is thus $0.
#####
#####
#####
#####
